Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Hot topics at SABCS 2020

Sangeetha Reddy • 16 Dec 2020
SABCS 2020
Breast Cancer
RxPONDER

Sangeetha Reddy, MD, UT Southwestern Medical Center, Dallas, TX, discusses practice-changing data presented at SABCS 2020 including results from the RxPONDER study (NCT01272037), Phase III trial evaluating whether the Oncotype DX® test can be used to spare chemotherapy in women with node-positive early-stage breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sangeetha Reddy

1:04
Are combination approaches the way forward for treating patients with triple-negative breast cancer?
Sangeetha Reddy • 12 Apr 2022
2:09
Triplet combination of chemotherapy, CD40 agonist, and Flt3 ligand in triple-negative breast cancer
Sangeetha Reddy • 12 Apr 2022
1:24
Combining chemotherapy, CD40 agonist, and Flt3 ligand in triple-negative breast cancer
Sangeetha Reddy • 12 Apr 2022
1:04
Future directions in triple-negative breast cancer research
Sangeetha Reddy • 12 Apr 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals